| 赵伟伟,王 峰,吴婷婷,邢海洋,王植荣,尹 雪.复荣通脉胶囊联合缬沙坦在保护原发性高血压患者靶器官损伤中的效果研究[J].,2024,(11):2159-2163 |
| 复荣通脉胶囊联合缬沙坦在保护原发性高血压患者靶器官损伤中的效果研究 |
| Study on the Effect of Furongtongmai Capsule Combined with Valsartan in Protecting Target Organ Injury in Patients with Essential Hypertension |
| 投稿时间：2023-10-23 修订日期：2023-11-19 |
| DOI：10.13241/j.cnki.pmb.2024.11.030 |
| 中文关键词: 原发性高血压 复荣通脉胶囊 缬沙坦 靶器官 疗效 |
| 英文关键词: Essential hypertension Furong Tongmai Capsule Valsartan Target organ Curative effect |
| 基金项目:河北省中医药管理局科研计划项目（2021291） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要 目的：研究复荣通脉胶囊联合缬沙坦在保护原发性高血压患者靶器官损伤中的效果。方法：2022年5月~2023年4月，河北省沧州中西医结合医院收治的原发性高血压患者92例分为缬沙坦联合安慰剂治疗的安慰剂组（46例）和缬沙坦联合复荣通脉胶囊治疗的复荣通脉组（46例），分组方法为随机抽签法，所有患者均治疗12周。统计两组治疗12周后的疗效，比较两组治疗前及治疗12周后血清细胞因子水平及血压控制情况、心、肾功能、颈动脉、脑血流情况。结果：治疗12周后，复荣通脉组总有效率高于安慰剂组（P<0.05）。治疗12周后两组血清同型半胱氨酸（HCY）、髓过氧化物酶（MPO）、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）、血肌酐（SCr）、尿微量白蛋白（mAlb）、β2微球蛋白（β2-MG）水平及舒张压、收缩压、夜间平均舒张压、夜间平均收缩压、日间平均舒张压、日间平均收缩压、左心房内径指数（LADI）、左心室质量指数（LVMI）、颈总动脉内膜-中层厚度（CCA-IMT）、颈内动脉内膜-中膜厚度（ICA-IMT）、颈动脉斑块数量与治疗前比较，降低，复荣通脉组低于安慰剂组（P<0.05）；左室射血分数（LVEF）、左椎动脉、右椎动脉、基底动脉平均血流速度与治疗前比较，升高，复荣通脉组高于安慰剂组（P<0.05）。结论：复荣通脉胶囊联合缬沙坦可调节原发性高血压患者血清细胞因子水平，改善其心、肾功能及颈动脉中层、中膜厚度，提高脑血流速度，可缓解靶器官损伤，具有较好的靶器官保护作用，疗效较好。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of Furong Tongmai capsule combined with valsartan in protecting the target organ injury in patients with essential hypertension. Methods: From May 2022 to April 2023, 92 patients with essential hypertension admitted to Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine in Hebei Province were divided into the placebo group (46 cases) treated with valsartan combined with placebo and the Furongtongmai group (46 cases) treated with valsartan combined with Furongtongmai capsule. The grouping method was random lottery, and all patients were treated for 12 weeks. The curative effects of the two groups after 12 weeks of treatment were counted, and the levels of serum cytokines, blood pressure control, cardiac and renal functions, carotid artery and cerebral blood flow were compared before and after 12 weeks of treatment. Results: After 12 weeks of treatment, the total effective rate of the Furongtongmai group was higher than that of the placebo group (P<0.05). After 12 weeks of treatment, the levels of serum homocysteine (HCY), myeloperoxidase (MPO), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor -α(TNF-α), serum creatinine (SCr), urinary microalbumin (mAlb), β2-microglobulin (β2-MG), diastolic pressure, systolic pressure and mean nocturnal diastolic pressure in the two groups. Left atrial diameter index (LADI), left ventricular mass index (LVMI), intima-media thickness of common carotid artery (CCA-IMT), intima-media thickness of internal carotid artery (ICA-IMT) and the number of carotid plaques decreased compared with those before treatment, and the Furongtongmai group was lower than the placebo group (P<0.05). Left ventricular ejection fraction (LVEF), average blood flow velocity of left vertebral artery, right vertebral artery and basilar artery were higher than before treatment, and the Furongtongmai group was higher than the placebo group (P<0.05). Conclusion: Furongtongmai Capsule combined with valsartan could regulate the level of serum cytokines in patients with essential hypertension, improve their heart and renal function, carotid intima-media thickness, increase cerebral blood flow velocity, relieve target organ injury, and had a good target organ protection effect and good curative effect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
